Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy

Circulation Journal

Volumn 70, Issue 3, 2006, Pages 335-341

  Zhang, Cuntai ^a,b   Yasuno, Shinji ^b   Kuwahara, Koichiro ^b   Zankov, Dimitar P ^c   Kobori, Atsushi ^b   Makiyama, Takeru ^b   Horie, Minoru ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b KYOTO UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Angiontensin II; Atrial fibrillation; Ventricular hypertrophy; Ventricular tachycardia

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CANDESARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETER; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART LEFT VENTRICLE HYPERTROPHY; INCIDENCE; MALE; MOUSE; NONHUMAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARRHYTHMIA; BENZIMIDAZOLES; BLOOD PRESSURE; DATA INTERPRETATION, STATISTICAL; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART FUNCTION TESTS; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VENTRICULAR FUNCTION, LEFT;

EID: 33644584458     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.70.335     Document Type: Article

References (35)

1. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987; 60: 560-565.
2. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death: Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22.
3. Rials SJ, Wu Y, Ford N, Pauletto FJ, Abramson SV, Rubin AM, et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation 1995; 91: 426-430.
4. Rials SJ, Wu Y, Xu X, Filart RA, Marinchak RA, Kowey PR. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 1997; 96: 1330-1336.
5. Rials SJ, Xu X, Wu Y, Liu T, Marinchack RA, Kowey PR. Restoration of normal ventricular electrophysiology in renovascular hypertensive rabbits after treatment with losartan. J Cardiovasc Pharmacol 2001; 37: 317-323.
6. Pitt B. Clinical trials of angiotensin receptor blockers in heart failure: What do we know and what will we learn? Am J Hypertens 2002; 15: 22S- 27S.
7. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
8. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
9. Himmelmann A, Svensson A, Bergbrant A, Hansson L. Losartan in essential hypertension: Effects on blood pressure and left ventricular mass. High Blood Press 1995; 4: 242-248.
10. Cuspidi C, Lonati L, Sampieri L. Effects of losartan on blood pressure and left ventricular mass in essential hypertension. High Blood Press 1998; 7: 1-5.
11. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-1462.
12. Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S, et al. Effects of losartan on hypertension and left ventricular mass: A long-term study. J Hum Hypertens 1998; 12: 505-510.
13. Martina B, Dieterle T, Weinbacher M, Battegay E. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension: A double-blind randomized controlled study. Cardiology 1999; 92: 110-114.
14. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
15. Kohya T, Yokoshiki H, Tohse N, Kanno M, Nakaya H, Saito H, et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: Beneficial effect of angiotensin II blockade. Circ Res 1995; 76: 892-899.
16. Mori T, Hayashi T, Sohmiya K, Okuda N, Shimomura H, Ohkita M, et al. Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. Circ J 2005; 69: 596-602.
17. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension 1994; 23: 587-592.
18. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
19. Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, et al. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 2005; 69: 671-676.
20. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
21. Wakimoto H, Maguire CT, Kovoor P, Hammer PE, Gehrmann J, Triedman JK, et al. Induction of atrial tachycardia and fibrillation in the mouse heart. Cardiovasc Res 2001; 50: 463-473.
22. Gavras H. Update on the clinical pharmacology of candesartan cilexetil. Am J Hypertens 2000; 13: 25S-30S.
23. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991; 88: 8277-8281.
24. 2-receptor knockout mice. Hypertension 1998; 32: 503-509.
25. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99: 3063-3070.
26. Saba S, Wang PJ, Estes NA 3rd. Invasive cardiac electrophysiology in the mouse: Techniques and applications. Trends Cardiovasc Med 2000; 10: 122-132.
27. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS, et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993; 87: 1328-1339.
28. De Mello WC, Danser AH. Angiotensin II and the heart: On the intracrine renin-angiotensin system. Hypertension 2000; 35: 1183-1188.
29. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423.
30. Rials SJ, Xu X, Wu Y, Marinchak RA, Kowey PR. Regression of LV hypertrophy with captopril normalizes membrane currents in rabbits. Am J Physiol 1998; 275: H1216- H1224.
31. Zeng J, Rudy Y. Early afterdepolarizations in cardiac myocytes: Mechanism and rate dependence. Biophys J 1995; 68: 949-964.
32. Priebe L, Beuckelmann DJ. Simulation study of cellular electric properties in heart failure. Circ Res 1998; 82: 1206-1223.
33. Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 1998; 98: 2404-2414.
34. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
35. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.